BioTrove Launches RapidFire 300 for in vitro ADME Discovery
News May 29, 2009
BioTrove, Inc. has announced the launch of its RapidFire® 300 system for high-throughput screening of in vitro ADME assays. Producing label-free data at six to eight seconds per sample, drug discovery researchers can now use the high-throughput, mass spectrometry based method to analyze in vitro ADME assays in a fraction of the time required for conventional HPLC mass spectrometry techniques.
The RapidFire 300 expands the in vitro ADME applications of the platform beyond drug-drug interaction (DDI) screening. DDI was first launched two years ago on the RapidFire 200 system and is used by numerous pharmaceutical and biotechnology companies to provide high quality DDI data at record throughput. This latest addition to the RapidFire screening tool kit will be introduced at the American Society for Mass Spectrometry’s (ASMS) 57th Annual Conference in Philadelphia, Pennsylvania, May 31-June 4.
As the newest addition to the RapidFire instrumentation portfolio, the RapidFire 300 system enables researchers to perform a wide range of in vitro ADME assays with 24-hour, unattended operation. The RapidFire-MS system streamlines drug discovery workflow, decreasing the processing time compared to conventional MS-based technologies and helps to eliminate bottlenecks in drug discovery while providing accurate results for data-driven decision making.
RapidFire 300 can fully integrate with any manufacturer’s triple quadrupole mass spectrometer and provide data compatible with customers’ existing laboratory information management systems.
The RapidFire 300 system can be used for a variety of in vitro ADME applications, including:
• CYP Inhibition.
• Metabolic Stability.
• P-Glycoprotein Inhibition.
• Plasma Protein Binding.
• Permeability Assays - Caco, PAMPA.
• CYP Induction.
Scientists from Boehringer Ingelheim, Merck and Johnson & Johnson will speak about advancing drug discovery and their experience with the RapidFire system on June 2, at 6:30 p.m., in BioTrove’s ASMS hospitality suite (Marriott Hotel, Suite J).
BioTrove researchers and customers will also present talks and posters at the conference on the RapidFire system as follows:
Monday, June 1
Oral Session – Chromatography-Mass Spectrometry Approaches to Increase Throughput in Discovery PK Assays, Ballroom B (10:10 a.m.)
A Novel and Integrated Platform for Fully Automated High-Throughput LCMSMS Analysis of in vitro ADME Samples; A. Luippold, T. Arnhold, W. Joerg, K. Klinder, K. Schumacher; Boehringer Ingelheim Pharma GmbH & Co KG.
Oral Session – Tandem MS of Whole Proteins and Protein Complexes, Room 201 (3:10 p.m.)
High Throughput Quantitative Screening Measuring Intact Proteins by a Novel Rapid Mass Spectrometric Approach; K. Alving, G. Asmussen, T. Gladysheva, J. Lillie, A. Cohen, B. Wang; Genzyme Corporation.
Poster Sessions – Drug Metabolism: High Throughput, Exhibit Hall AB (10:30 a.m. - 2:30 p.m.)
P 437: Application of the BioTrove RapidFire® Ultra-fast Online SPE-MS/MS System for Compound-specific Analysis of in-vitro ADME Samples; A. Paiva, A. Wagner, X. Cai, Y. Li, J. Kolb, J. Herbst, C. Conway, H. Weller, W. Shou; Bristol-Myers Squibb.
P 438: Evaluation of accurate mass TOF-MS for use in high throughput CYP450 inhibition screening; W. LaMarr, M. Romm, N. Parikh, L. Frick, C. Özbal; BioTrove, Inc
Thursday, June 4
Poster Sessions – High Throughput Analysis/Robotics, Exhibit Hall AB (10:30 a.m. - 2:30 p.m.)
P 669: Label Free High-Throughput Whole Protein Kinase Screening Assay; M. Romm, N. Parikh, T. Stanley, J. Williams, W. Lamarr, C. Özbal; BioTrove, Inc., GlaxoSmithKline.
P 677: Discovery of Novel Inhibitors of Serine Palmitoyltransferase (SPT) by Mass Spectrometry-Based High-Throughput Screening (HTS); P. Meyn, P. Maresca, W. Lamarr, P. Rye, M. Brooks, A. Babbs, M. Procter, D. Pan, C. Özbal, A. Garton; OSI Pharmaceuticals, BioTrove, Inc., Prosidion Limited.
BioTrove representatives will be available throughout the conference to discuss RapidFire solutions at Booth #66 during the day and in Hospitality Suite J at the Marriott Hotel on June 1-3.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.